Covance has introduced Early Phase Development Solutions, a new multi-disciplined approach to early drug development that aims to generate greater value in asset development and achieve accelerated delivery timelines.
 
The service provides access to a molecule solution team from nonclinical, clinical and regulatory disciplines, that’s experienced in early drug discovery and development. This dedicated team and insight aims to ensure strategic program design that allows for clear decision-making and value addition to the molecule from nonclinical through to first-in-human ready, Phase II ready, proof-of-concept and full-development ready.  
 
“Our market research showed that the two greatest challenges our biopharma clients face today are continuity of a drug development program – both scientific and operational – and the need for stronger outsourcing partnerships,” said Steve Street, Ph.D., vice president and global general manager, Covance Early Development. “We created Early Phase Development Solutions to help our clients overcome those challenges – something that Covance is uniquely positioned to do given the depth and breadth of our services and expertise from the CRO industry as well as global pharma.”